



ORIGINAL ARTICLE

The Accuracy of Japanese Administrative Data in Identifying Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Keisuke Anan^{1,2,3}, Yuki Kataoka^{1,3,4}, Kazuya Ichikado², Kodai Kawamura², Takeshi Johkoh⁵, Kiminori Fujimoto⁶, Kazunori Tobino⁷, Ryo Tachikawa⁸, Hiroyuki Ito⁹, Takahito Nakamura¹⁰, Tomoo Kishaba¹¹, Minoru Inomata¹², Yosuke Yamamoto¹

ABSTRACT

BACKGROUND

This study aimed to develop criteria for identifying patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) from Japanese administrative data and validate the preexisting criteria.

METHODS

This retrospective, multi-center validation study was conducted at eight institutes in Japan to verify the diagnostic accuracy of the disease name for AE-IPF. We used the Japanese Diagnosis Procedure Combination data to identify patients with a disease name that could meet the diagnostic criteria for AE-IPF, who were admitted to the eight institutes from January 2016 to February 2019. As a reference standard, two respiratory physicians performed a chart review to determine whether the patients had a disease that met the diagnostic criteria for AE-IPF. Furthermore, two radiologists interpreted the chest computed tomography findings of cases considered AE-IPF and confirmed the diagnosis. We calculated the positive predictive value (PPV) for each disease name and its combination.

RESULTS

We included 830 patients; among them, 216 were diagnosed with AE-IPF through the chart review. We combined the groups of disease names and yielded two criteria: the criteria with a high PPV (0.72 [95% confidence interval 0.62 to 0.81]) and that with a slightly less PPV (0.61 [0.53 to 0.68]) but more true positives. Pre-existing criteria showed a PPV of 0.40 (0.31 to 0.49).

CONCLUSION

The criteria derived in this study for identifying AE-IPF from Japanese administrative data show a fair PPV. Although these criteria should be carefully interpreted according to the target population, our findings could be utilized in future database studies on AE-IPF.

KEY WORDS

idiopathic pulmonary fibrosis, acute exacerbation, validation, administrative data

¹ Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan

² Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan

³ Systematic Review Workshop Peer Support Group (SRWS-PSG), Osaka, Japan

⁴ Department of Internal Medicine, Kyoto Min-Iren Asukai Hospital, Kyoto, Japan

⁵ Department of Radiology, Kansai Rosai Hospital, Hyogo, Japan

⁶ Department of Radiology, Kurume University School of Medicine, Fukuoka, Japan

⁷ Department of Respiratory Medicine, Iizuka Hospital, Fukuoka, Japan

⁸ Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan

⁹ Department of Pulmonology, Kameda Medical Center, Chiba, Japan

¹⁰ Department of Internal Medicine, Nara Prefecture Seiwa Medical Center, Nara, Japan

 ¹¹ Department of Respiratory Medicine, Okinawa Chubu Hospital, Okinawa, Japan
 ¹² Department of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo,

Japanese Red Cross Medical Center, Tokyo, Japan

Corresponding author: Yosuke Yamamoto Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho Sakyo-ku; Kyoto-City 606-8501, Japan

E-mail: yamamoto.yosuke.5n@kyoto-u.ac.jp

Received: July 6, 2021 Accepted: August 22, 2021 J-STAGE Advance published date: February 9, 2022

No. 22008

© 2022 Society for Clinical Epidemiology

BACKGROUND

diopathic pulmonary fibrosis (IPF) is a rare disease with a poor prognosis that is characterized by chronic progressive lung fibrosis. Although IPF is rare, it has a worse prognosis than numerous cancer types [1]. Moreover, hospitalization and mortality rates attributable to IPF have increased over recent years, which is suggestive of an increasing burden of this disease on healthcare services worldwide [2-4]. During the disease course, acute exacerbation (AE) may occur at an annual frequency of approximately 5-15%; further, the mortality rate is reported to be approximately 50-60% [5, 6]. Few randomized controlled trials (RCTs) with limited external validity have investigated AE-IPF [7, 8]. Therefore, there is a need for large observational studies on a wider patient population using real-world data to complement RCTs [9].

However, there have been rare seen large-scale database studies on AE-IPF. This could be attributed to the difficulty in identifying cases. In large-scale database research, case identification is essential, with validation studies being crucial for this purpose. The REporting of studies Conducted using Observational Routinely collected health Data (RECORD) statement mentions that "Any validation studies of the codes or algorithms used to select the population should be referenced" [10]. Regarding AE-IPF, one validation study has been performed in the US [11]; however, the positive predictive value (PPV) was not very high (0.621 [95% confidence interval [CI] 0.533 to 0.704]). Additionally, it remains unclear whether the data can be applied in other countries.

This study aimed to develop criteria for identifying patients with AE-IPF, as well as validate the criteria in the previous study, using multi-center chart data in Japan.

METHODS

We performed and reported this study in accordance with the reporting guidelines for assessing the quality of validation studies of health administrative data (**Table S1**) [12].

SETTINGS AND PATIENTS

This retrospective, multicenter, validation study was conducted to verify the diagnostic accuracy of the disease name for AE-IPF. We performed study in eight Japanese tertiary hospitals: Saiseikai Kumamoto Hospital, Hyogo Prefectural Amagasaki General Medical Center, Iizuka Hospital, Kobe City Medical Center General Hospital,

54

Kameda Medical Center, Hoshigaoka Medical Center, Okinawa Chubu Hospital, and the Japanese Red Cross Medical Center.

We included patients aged ≥ 40 years with a disease name that could meet the diagnostic criteria for AE-IPF (**Table 1**), who were admitted to the aforementioned eight institutes from January 2016 to February 2019. These criteria were developed in advance by two respiratory specialists. We excluded patients with disease names for secondary interstitial pneumonia, including collagen vascular disease-associated interstitial lung disease and chronic and hypersensitivity pneumonitis, as well as those for malignant neoplasms (**Table 2**). We did not exclude patients with disease names for malignant neoplasms with the suffixes "post-operation" or "postradiotherapy". We ignored all "suspected" disease names.

Regarding disease names, we extracted data from the Diagnosis Procedure Combination (DPC), which was launched at Japanese acute-care hospitals across the country in 2003 [13, 14]. The following data were extracted from the DPC: some clinical information (e.g. age, gender, etc.), admission route (e.g. scheduled or emergency admission), diagnoses, surgeries and procedures, medications, outcomes, etc. The patients were recorded with diagnostic names using the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes. The diagnoses included the following six categories: main diagnosis, diagnosis that triggered hospitalization, diagnosis using the most medical resources, diagnosis using the second most medical resources, comorbidities present at admission, and conditions occurring after admission. One diagnostic name is coded for each main diagnosis, diagnosis that triggered hospitalization, diagnosis using the most medical resources, and diagnosis using the second most medical resources. Meanwhile, up to 10 diagnostic names can be coded for comorbidities present at admission and conditions occurring after admission. Furthermore, in the Japanese DPC data, modifiers can be added to the disease name in ICD-10 (e.g., regions such as left and right, recurrence, acute exacerbation, suspected, etc.).

This study was approved by the Ethics Committee of leading institute of this study (Kyoto University Graduate School and Faculty of Medicine) (Approved Number: R2071) and other committed institutes. The requirement for written informed consent from the participants was waived because of the retrospective design. Meanwhile, we offered the patients an opportunity to opt-out.

Table 1 Disease names adopted as inclusion criteria										
ICD-10 code 1	disease name 1*	suffix	ICD-10 code 2	disease name 2**	suffix	emergency admission				
J841	idiopathic pulmonary fibrosis	AE	_	_	_					
J841	idiopathic interstitial pneumonia	AE	_	_	—	_				
J841	usual interstitial pneumonia	AE	_	-	—	—				
J841	pulmonary fibrosis	AE	_	_	_	—				
J841	diffuse interstitial pneumonia	AE	_	_	—	—				
J849	interstitial pneumonia	AE	_	_	_	—				
J841	acute interstitial pneumonia	—	_	-	—	—				
J841	diffuse interstitial pneumonia	—	_	_	—	_				
J841	diffuse alveolar damage	—	_	-	—	—				
J80	acute respiratory distress syndrome	—	_	_	—	_				
J984	acute lung injury	—	_	-	—	—				
J702	acute drug—induced interstitial lung disorders	—	_	-	-	-				
J704	drug-induced interstitial pneumonia	—	_	-	—	_				
J10~J111 J15~189 J690	pneumonia, Influenza, aspiration pneumonia	_	J841	idiopathic pulmonary fibrosis	AE	_				
		_	J841	idiopathic interstitial pneumonia	AE	_				
		_	J841	usual interstitial pneumonia	AE	_				
		—	J841	pulmonary fibrosis	AE	-				
		_	J841	diffuse interstitial pneumonia	AE	_				
		—	J841	interstitial pneumonia	AE	-				
		_	J841	idiopathic pulmonary fibrosis	_	_				
		—	J841	idiopathic interstitial pneumonia	_	_				
		—	J841	usual interstitial pneumonia	—	_				
		—	J841	pulmonary fibrosis	—	-				
		—	J841	diffuse interstitial pneumonia	—	_				
		—	J841	interstitial pneumonia	_	_				
J841	idiopathic pulmonary fibrosis	—	_	_	—	0				
J841	idiopathic interstitial pneumonia	—	_	_	—	0				
J841	usual interstitial pneumonia	—	_	_	—	0				
J841	pulmonary fibrosis	—	—	-	—	0				
J841	diffuse interstitial pneumonia	_	_	_	_	0				
J849	interstitial pneumonia	_	_	_	_	0				

AE, acute exacerbation; DPC, diagnosis procedure combination; ICD-10, the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision
* Disease name in any categories in the DPC data
** Disease name in co-morbidities present at admission and conditions occurring after admission

Table 2 Disease names adopted as exclusion criteria						
ICD-10 code disease name*						
C00~C96	malignant neoplasms**					
D860	sarcoidosis of lung					
J60	coal worker's pneumoconiosis					
J61	asbestosis					
J64	pneumoconiosis					
J67	hypersensitivity pneumonitis due to organic dust					
J990·M0510	rheumatoid arthritis-associated interstitial lung disease					
J991·M351	collagen vascular disease-associated interstitial lung disease					
J991·M330	juvenile dermatomyositis-associated interstitial lung disease					
J991·M321	systemic lupus erythematosus-associated interstitial lung disease					
J991·M332	polymyositis-associated interstitial lung disease					
J991·M331	dermatomyositis-associated interstitial lung disease					
J991·M313	lung involvement in granulomatosis with polyangiitis					
M348	lung involvement in systemic sclerosis					
* Disease name in any category in the DPC data ** not exclude if they have attached suffix of "post-operation" or "post-radiotherapy".						

REFERENCE STANDARD

We confirmed the AE-IPF diagnosis using the following two steps:

1) At least two respiratory physicians at each institute reviewed the medical records and chest computed tomography (CT) findings on admission. Subsequently, they determined whether the patients met the following diagnostic criteria: an official ATS/ERS/JRS/ALAT clinical practice guideline for IPF diagnosis [15] and the international working group diagnostic criteria for AE-IPF [16]. An IPF diagnosis was determined if UIP or probable UIP pattern was observed on HRCT findings, even without surgical lung biopsy (SLB). If SLB was performed, IPF was considered based on specific combinations of HRCT and histopathological patterns following the ATS/ERS/JRS/ALAT clinical practice guidelines [15]. Discrepancies were resolved through discussion or consultation with a third respiratory physician, as appropriate.

2) Two expert chest radiologists interpreted chest CT findings of cases considered to be AE-IPF in 1) and determined whether the patients met the aforementioned two diagnostic criteria. If both radiologists considered that a case was not AE-IPF, it was determined as not AE-IPF. On the other hand, if a case was considered as not as

AE-IPF by only one radiologist, the case was determined as AE-IPF.

Multidisciplinary discussion (MDD), which is held for diagnostic decision-making regarding patients with interstitial lung disease who are clinically suspected to have IPF, has been described in the official ATS/ERS/JRS/ ALAT clinical practice guideline [15]. However, MDD is a conditional recommendation that is not widely held in Japanese hospitals. Therefore, we decided not to consider MDD as a diagnostic requirement.

DEVELOPING CRITERIA

First, we assessed the diagnostic accuracy of each disease name in the inclusion criteria, with disease names showing high diagnostic accuracy being adopted without modification. Next, we explored combinations of disease names with high diagnostic accuracy for disease names with a high number of true positives. We sought to create two criteria: 1) the criteria with the higher PPV (narrow criteria) and 2) criteria with slightly less PPV but more true positives (broad criteria). Based on previous studies [11, 17, 18], we excluded disease names of secondary interstitial lung diseases (ILDs) and included those of acute respiratory failure (ARF) (**Table 3**). Further, we

IDD other than PICD-10 codediscase nameC966Langerhans-cell histico;tosis*D809SarcoidosisD756Upidoses1982 B31diopathic pulmonary henosiderosisD80calvoder's preumoconiosis*D810abestosis*161salescisos*162salescisos*163uspecified pneumoconiosis*164uspecified pneumoconiosis*164supersensitivity pneumonitis*176Palmonary cesinophilia, not elsewhere classified187Chronic and other pulmocary manifestations due to radiation188Chronic and other pulmonary manifestations due to radiation170Septiantry conditions due to chemicals gases, fumes, and vapors171Respiratory conditions due to chemicals gases, fumes, and vapors172Respiratory conditions due to chemicals gases, fumes, and vapors173Respiratory conditions due to chemicals gases, fumes, and vapors174Respiratory conditions due to chemicals gases, fumes, and vapors175Respiratory conditions due to chemicals gases, fumes, and vapors176Respiratory conditions due to chemicals gases, fumes, and vapors178Respiratory conditions due to chemicals gases, fumes, and vapors179Respiratory disorders in disease classified elsewhere180Respiratory disorders181Godpasturé spratomo181Godpasturé spratomo181Godpasturé spratomo181Godpasturé spratomo181Godpasturé	Table 3 ICD-10 code and acute respiratory	s for interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF failure.
ICP-01 codeissea nameCSP60Aigerhans-cell histicoytosis*D869SacoidosisF750JajdoseD978ES1Aigotosis Palensonis PalensonisB761Calvarker's pnumoconiosis*B701Sacois ralcosisB701Sacois ralcosisB711Sacois ralcosisB721Sacois ralcosisB731Sacois ralcosisB741Sacois ralcosisB741Sacois ralcosisB742Sacois ralcosisB743Sacois ralcosisB743Sacois ralcosisB744Sacois ralcosisB744Sacois ralcosisB745Sacois ralcosisB745Sacois ralcosisB746Sacois ralcosisB747Sacois ralcosisB748Sacois ralcosis da tos chemicals, gase, fume, and vaporsB749Sacois ralcosis da tos chemicals, gase, fume, and vaporsB740Sacois ralcosis da tos chemicals, gase, fume, and vaporsB741Sacois chemical gases fasified elsewhereB741Sacois chemical gases fasified elsewhereB742Sacois chemical gases fasified elsewhereB743Sacois chemical gases fasified elsewhereB744Sacois chemical gases fasified elsewhereB745Sacois chemical gases fasified elsewhereB745	ILDs other than IPF	
C966Iargerhans-cell histicoytosis*D869SarcoidosisF750Lipidoses1998-E831Idiopathic pulmonary hemosiderosisE85Amyloidosis160cola worker's pneumoconiosis*161sibestosis*162sibestosis*163beryllosis and other inorganic dusts164sipecified pneumoconiosis*174sipecified pneumoconiosis*184Pulmonary cosinophilia, not elsewhere classified187Varinsic allergic alveolitis184Chonic respiratory conditions due to chemicals, gases, fumes, and vapors174Sipinatory conditions due to chemicals, gases, fumes, and vapors178Chonic and other pulmonary fumosita184Sipinatory conditions due to adjation197Sipinatory conditions due to adjation198Sipinatory conditions due to adjation199Sipinatory dulmonary fibrosis191Sipinatory dulmorary fibrosis193Sipinatory dulmorary fibrosis193Sipinatory dulmorary fibrosis193Sipinatory dustris miscasci fiel elsewhere193Sipinatory dustris miscasci fiel el	ICD-10 code	disease name
D890Arciolosis1000000000000000000000000000000000000	C966	Langerhans-cell histiocytosis*
E756Ipidoes1979Biophic pulmonary hemosiderosis1960Amyloidosis1961cola worker's pneumoconiosis*1961abetosis*1971Biolosis or talcosis1972Biolosis and other inorganic dusts1974Biophicamic dusts1974Biophicamic dusts1974Biophicamic dusts1974Biophicamic dusts1974Biophicamic dust or chastified1974Biophicamic dust or chastified acternal agents1974Chronic respiratory conditions due to chemicals, gaser, fumes, and vapors1974Chronic respiratory conditions due to chemicals, gaser, fumes, and vapors1974Rovini crespiratory conditions due to chemicals, gaser, fumes, and vapors1974Rovini crespiratory conditions due to chemicals, gaser, fumes, and vapors1974Rovini crespiratory conditions due to chemicals, gaser, fumes, and vapors1974Rovini crespiratory conditions due to chemicals, gaser, fumes, and vapors1974Rovini crespiratory conditions due to chemicals, gaser, fumes, and vapors1974Rovini crespiratory conditions due to chemicals, gaser, fumes, and vapors1974Rovini crespiratory conditions due to chemicals, gaser, fumes, and vapors1974Rovini crespiratory conditions due to chemicals, gaser, fumes, and vapors1974Rovini crespiratory conditions due to chemicals, gaser, fumes, and vapors1974Rovini crespiratory crespiratory conditions1975Rovini crespiratory crespiratory crespiratory crespiratory crespiratory crespiratory crespiratory crespiratory	D869	Sarcoidosis
vierterent of the second sec	E756	Lipidoses
Basi Amyloidosis IG0 coal worker's pneumoconiosis* IG1 abestosis* IG2 silicosis or talcosis IG2 silicosis or talcosis IG4 unspecified pneumoconiosis* IG4 unspecified pneumoconiosis* IG4 sepriliosis and other inorganic dusts IG4 unspecified pneumoconiosis* IG4 hypersensitivity pneumonitis* IS2 Pulmonary cosinophilia, not elsewhere classified IS4 Chronic respiratory conditions due to chemicals, gases, fumes, and vapors I701 Chronic and other pulmonary manifestations due to radiation I708 Respiratory conditions due to other specified external agents I840 Alveolar and parieto-alveolar conditions I841 Postinflammatory pulmonary fibrosis I99 Respiratory disorders in diseases classified elsewhere K50 Regional entertitis M310 Goodpasture's syndrome M313 Vergener's granulomatosis M314 Polymositis M320 Systemic lupus erythematosus M314 In	J998·E831	Idiopathic pulmonary hemosiderosis
A160worker's pneumoconiosis*161abestosis162silcosis or talcosis163berylliosis and other inorganic dusts164unspecified pneumoconiosis*164pyersensitivity pneumonitis*167byersensitivity pneumonitis*182Chronic respiratory conditions due to chemicals, gases, fumes, and vapors170Chronic respiratory conditions due to chemicals, gases, fumes, and vapors1701Chronic and other pulmonary manifestations due to radiation1708Respiratory conditions due to other specified external agents1708Respiratory conditions due to other specified external agents1708Respiratory disorders in diseases classified elsewhere1709Respiratory disorders in diseases classified elsewhere1701Goodpasture's syndrome1701Goodpasture's syndrome1701Microscopic polyangiitis1701Microscopic polyangiitis1701Systemic lupus erythematosus1701Systemic lupus erythematosus1701Systemic lupus erythematosus1701Sigend's disease1702Sigend's disease1703Sigend's disease1704Sigend's disease1705Sigend's disease1705Sigend's disease1706Netrolis prediction sit1707Sigend's disease1708Sigend's disease1709Netrolis prediction sit1701Sigend's disease1701Sigend's disease1702 <td>E85</td> <td>Amvloidosis</td>	E85	Amvloidosis
Join asbetosis* Join silicosis or talcosis Join berylliosis and other inorganic dusts Join unspecified pneumoconiosis* Join muspecified pneumoconiosis* Join pulmonary cosinophilia, not elsewhere classified Join Pulmonary cosinophilia, not elsewhere classified Join Chronic respiratory conditions due to chemicals, gases, fumes, and vapors Join Chronic respiratory conditions due to other specified external agents Join Aveolar and parieto-alveolar conditions Join Aveolar and parieto-alveolar conditions Join Postinflammatory pulmonary fibrosis Join Respiratory disorders in diseases classified desewhere K50 Regional entertitis MJ10 Goodpasture's syndrome MJ13 Wergener's granulomatosis MJ30 Systemic lupus erythematosus MJ31 Oter specified necrotizing vasculopathies MJ32 Systemic sclerosis* MJ33 MS30 Systemic sclerosis* MJ34 Augi novlement in systemic sclerosis* MJ35 Mero	J60	coal worker's pneumoconiosis*
Jac silicosis or talcosis J62 silicosis or talcosis J63 berylliosis and other inorganic dusts J64 unspecified pneumoconiosis* J67 hypersensitivity pneumonitis* J68 Pulmonary cosinophilia, not elsewhere classified J72 Extrinsic allergic alveolitis J78 Chronic respiratory conditions due to chemicals, gases, fumes, and vapors J74 Chronic and other pulmonary manifestations due to radiation J78 Respiratory conditions due to other specified external agents J79 Respiratory disorders in diseases classified elsewhere J79 Respiratory disorders in diseases classified elsewhere J79 Respiratory disorders in diseases classified elsewhere J70 Respiratory disorders in diseases classified elsewhere J70 Respiratory disorders in diseases classified elsewhere J70 Respiratory disorders in diseases classified elsewhere J71 Respiratory disorders in diseases classified elsewhere J72 Respiratory disorders in diseases classified elsewhere J73 Respiratory disorders in diseases classified elsewhere J73 Systemic	J61	asbestosis*
J63 berylliosis and other inorganic dusts J64 unspecified pneumoconiosis* J67 hypersensitivity pneumonitis* J82 Pulmonary eosinophilia, not elsewhere classified J82 Extrinsic allergic alveolitis J644 Chronic respiratory conditions due to chemicals, gases, fumes, and vapors J701 Chronic respiratory conditions due to other specified external agents J708 Respiratory conditions due to other specified external agents J840 Alveolar and parieto-alveolar conditions J841 Postinflammatory pulmonary fibrosis J840 Regional enteritis M050 Regional enteritis M10 Goodpasturés syndrome M131 Wegener's granulomatosis M141 Microscopic polyangiitis M132 Systemic lupus erythematosus M133 Permatomyositis M340 Systemic sclerosis* M350 Systemic sclerosis M340 Systemic sclerosis* M350 Systemic sclerosis M351 ung involvement in systemic sclerosis* M351 A	I62	silicosis or talcosis
Joint of the constant of the consteconstant of the constant of the constant of the cons	163	bervlliosis and other inorganic dusts
Procession Procession PG7 hypersensitivity pneumonitis* P82 Pulmonary eosinophilia, not elsewhere classified P82 Extrinsic allergic alveolitis P64 Chronic respiratory conditions due to chemicals, gases, fumes, and vapors P70 Chronic and other pulmonary manifestations due to radiation P70 Chronic and other pulmonary manifestations due to radiation P70 Respiratory conditions due to other specified external agents P84 Alveolar and parieto-alveolar conditions P84 Postinflammatory pulmonary fibrosis P94 Respiratory disorders in diseases classified elsewhere K50 Regional enteritis M310 Goodpasture's syndrome M313 Wegener's granulomatosis M314 Vegener's granulomatosus M315 Other specified necrotizing vasculopathies M320 Systemic lupus erythematosus M330 Dermatomyositis M340 Systemic sclerosis M340 Systemic sclerosis M350 Sjogren's disease M351 other orerlap syndrome <t< td=""><td>164</td><td>unspecified pneumoconiosis*</td></t<>	164	unspecified pneumoconiosis*
Part of a presentation of presentation 182 Pulmonary cosinophilia, not elsewhere classified 182 Extrinsic allergic alveolitis 184 Chronic respiratory conditions due to chemicals, gases, fumes, and vapors 1701 Chronic and other pulmonary manifestations due to radiation 1708 Respiratory conditions due to other specified external agents 1840 Alveolar and parieto-alveolar conditions 1841 Postinflammatory pulmonary fibrosis 199 Respiratory disorders in diseases classified elsewhere K50 Regional enteritis M05, M06 Rheumatoid arthritis M310 Goodpasture's syndrome M313 Wegener's granulomatosis M314 Vicroscopic polyangiitis M315 Other specified necrotizing vasculopathies M320 Systemic lupus erythematosus M334 Systemic sclerosis M348 Lung involvement in systemic sclerosis* M350 Sigren's disease M351 other overlap syndrome M352 Sigren's disease M353 other overlap syndrome	167	hypersensitivity pneumonitis*
Pail Feature and private for the matric classified 182 Extrinsic allergic alveolitis 1684 Chronic respiratory conditions due to chemicals, gases, fumes, and vapors 1701 Chronic and other pulmonary manifestations due to radiation 1708 Respiratory conditions due to other specified external agents 1840 Alveolar and parieto-alveolar conditions 1841 Postinflammatory pulmonary fibrosis 1841 Postinflammatory pulmonary fibrosis 199 Respiratory disorders in diseases classified elsewhere K50 Regional enteritis M05, M06 Rheumatoid arthritis M310 Goodpasture's syndrome M313 Wegener's granulomatosis M314 Other specified necrotizing vasculopathies M320 Systemic lupus erythematosus M331 Dermatomyositis M332 Polymyositis M340 Systemic sclerosis* M340 Systemic sclerosis* M350 Sigoren's disease M351 Other overlap syndrome M45 Ankylosing spondylitis Roter overlap	182	Pulmonary eosinophilia, not elsewhere classified
Job Construction Construction Job Chronic respiratory conditions due to chemicals, gases, fumes, and vapors Jr01 Chronic and other pulmonary manifestations due to radiation Jr03 Respiratory conditions due to other specified external agents Jr840 Alveolar and parieto-alveolar conditions Jr840 Postinflammatory pulmonary fibrosis Jr841 Postinflammatory pulmonary fibrosis Jr840 Respiratory disorders in diseases classified elsewhere K50 Regional enteritis M310 Goodpasture's syndrome M313 Wegener's granulomatosis M314 Vescoric polyangiitis M315 Other specified necrotizing vasculopathies M321, M329 Systemic lupus erythematosus M332 Polymyositis M340, M341, M349 Systemic sclerosis* M350 Sjogren's disease M351 other overlap syndrome M351 Alveolorig spondylitis M360 Neurofibromatosis M370 Neurofibromatosis M380 Neurofibromatosis M381 Neurofibromatosis <	182	Extrinsic allergic alveolitis
NoveClinic respiratory condutions due to cherimicas, gaces, runks, and vapors7701Chronic and other pulmonary manifestations due to radiation7708Respiratory conditions due to other specified external agents7840Alveolar and parieto-alveolar conditions7841Postinflammatory pulmonary fibrosis799Respiratory disorders in diseases classified elsewhere708Regional enteritis709Regional enteritis701Goodpasture's syndrome7031Goodpasture's syndrome7031Microscopic polyangitis7031Microscopic polyangitis7032Systemic lupus erythematosus70330M331, M33970340Systemic lupus erythematosus70350Systemic sclerosis*70340Systemic sclerosis*70350Sjogren's disease70360Neurofibromatosis70450Neurofibromatosis7050Sigs spondylitis7050Neurofibromatosis7050Sigs spondylitis7050Sigs spondylitis7050Sigs spondylitis7050Sigs spondylitis7050Sigs sclerosis7050Sigs spondylitis7050Sigs spondylitis7050Sigs spondylitis7050Sigs spondylitis7050Sigs sen anme7050Sigs sen anme7050Sigs sen anme7050Sigs sen anmes as exclusion criteria	1684	Chronic respiratory conditions due to chemicale gases fumes and vanors
For and event particular y numerotations due to relation1708Respiratory conditions due to other specified external agents1840Alveolar and parieto-alveolar conditions1841Postinflammatory pulmonary fibrosis199Respiratory disorders in diseases classified elsewhereK50Regional enteritisM05, M06Rheumatoid arthritisM310Goodpasture's syndromeM313Wegener's granulomatosisM314Microscopic polyangiitisM315Other specified necrotizing vasculopathiesM320, M331, M339DermatomyositisM340, M341, M349Systemic lupus erythematosusM350Systemic sclerosisM350Sjogren's diseaseM351other overlap syndromeM45Ankylosing spondylitisQ850NeurofibromatosisQ851Tuberous sclerosisCD-10 codedisease name1960acute respiratory failure* We already excluded the: disease names as exclusion criteria	1701	Chronic and other pulmonary manifestations due to radiation
ProductionReceptiatory conditions due to other specified external agents1840Alveolar and parieto-alveolar conditions1841Postinflammatory pulmonary fibrosis199Respiratory disorders in diseases classified elsewhereK50Regional enteritisM05, M06Rheumatoid arthritisM310Goodpasture's syndromeM313Wegener's granulomatosisM314Microscopic polyangiitisM315Other specified necrotizing vasculopathiesM320, M331, M339DermatomyositisM340, M341, M349Systemic lupus erythematosusM350Gjogren's diseaseM351ung involvement in systemic sclerosis*M351Aikylosing spondylitisM351Aikylosing spondylitisQ850NeurofibromatosisQ851Tiberous sclerosisAcute respiratory failureICD-10 codedisease name* We already excluded thes: Usease names as exclusion criteria	1708	Pachizatory conditions due to other specified external agents
Note of a fixed and parteto-avector continions1941Postinflammatory pulmonary fibrosis199Respiratory disorders in diseases classified elsewhereK50Regional enteritisM05, M06Rheumatoid arthritisM310Goodpasture's syndromeM313Wegener's granulomatosisM314Microscopic polyangiitisM315Other specified necrotizing vasculopathiesM320, M331, M339DermatomysitisM330, M331, M339DermatomysitisM340, M341, M349Systemic lupus erythematosusM350Siggren's diseaseM350Siggren's diseaseM351Other overlap syndromeM351Other overlap syndromeM351Other overlap syndromeM55NeurofibromatosisM350Siggren's diseaseQ850NeurofibromatosisAcute respiratory failureICD-10 codedisease names as exclusion criteria	1940	Alvolar and parioto alvolar conditions
Jose aForstmannatory publication process199Respiratory disorders in diseases classified elsewhereK50Regional enteritisM05, M06Rheumatoid arthritisM310Goodpasture's syndromeM313Wegener's granulomatosisM314Microscopic polyangiitisM315Other specified necrotizing vasculopathiesM320, M331, M339DermatomyositisM330, M331, M339DermatomyositisM340, M341, M449Systemic sclerosis*M350Signern's diseaseM351other overlap syndromeM351other overlap syndromeM351NeurofibromatosisM351NeurofibromatosisM352NeurofibromatosisM350Signern's diseaseM350NeurofibromatosisM351other overlap syndromeM45NeurofibromatosisRespiratory failureICD-10 codedisease names as exclusion criteria* We already excluded thes - times as exclusion criteria	1940	Postinflammatory pulmonery fibrosis
PSPRespiratory disorders in diseases classified elsewhereK50Regional enteritisM05, M06Rheumatoid arthritisM310Goodpasture's syndromeM313Wegener's granulomatosisM314Microscopic polyangiitisM315Other specified necrotizing vasculopathiesM321, M329Systemic lupus erythematosusM330, M331, M339DermatomyositisM340, M341, M349Systemic sclerosisM350Systemic sclerosisM350Sigoren's diseaseM351other overlap syndromeM45Ankylosing spondylitisQ851Tuberous sclerosisAcute respiratory failuretiberous sclerosisLDP-10 codedisease name* We already excluded terse strassing as exclusion criteria	100	Postimaninatory punnonary norosis
KS0Regional enternisM05, M06Rheumatoid arthritisM310Goodpasture's syndromeM313Wegener's granulomatosisM314Microscopic polyangiitisM318Other specified necrotizing vasculopathiesM320, M321, M329Systemic lupus erythematosusM330, M331, M339DermatomyositisM340, M341, M349Systemic sclerosisM350Systemic sclerosisM351Giogren's diseaseM350Sjogren's diseaseM351other overlap syndromeM45NeurofibromatosisQ850NeurofibromatosisAcute respiratory failureIuberous sclerosis failureIDP-10 codedisease names as exclusion criteria	J99 K50	Respiratory disorders in diseases classified elsewhere
M06, M06Recurrational arthritisM310Goodpasture's syndromeM313Wegener's granulomatosisM314Microscopic polyangiitisM315Other specified necrotizing vasculopathiesM321, M329Systemic lupus erythematosusM330, M331, M339DermatomyositisM340, M341, M349Systemic sclerosisM350Systemic sclerosisM350Sigren's diseaseM351other overlap syndromeM45Ankylosing spondylitisQ850Iuberous sclerosisAcute respiratory failureIuberous sclerosisICD-10 codedisease name1960acute respiratory failure	K50	
M310Goodpatures syndromeM313Wegener's granulomatosisM314Microscopic polyangiitisM318Other specified necrotizing vasculopathiesM321, M329Systemic lupus erythematosusM330, M331, M339DermatomyositisM340, M341, M349Systemic sclerosisM340Jugenerit in systemic sclerosis*M350Sjogren's diseaseM351other overlap syndromeM450Ankylosing spondylitisQ851Tuberous sclerosisQ851Tuberous sclerosisLCD-10 codedisease name1960acute respiratory failure* We already excluded these tisease names as exclusion criteria	M05, M06	Rheumatoid arthritis
M313Wegener's granulomatosisM317Microscopic polyangiitisM318Other specified necrotizing vasculopathiesM321, M329Systemic lupus erythematosusM330, M331, M339DermatomyositisM330, M331, M349PolymyositisM340, M341, M349Systemic sclerosisM350Systemic sclerosis*M350Sjogren's diseaseM351other overlap syndromeM45Ankylosing spondylitisQ850NeurofibromatosisQ851Tuberous sclerosisCDP-10 codedisease name1960acute respiratory failure* We already excluded these to marks as exclusion criteria	M310	Goodpastures syndrome
M317Microscopic polyangiitisM318Other specified necrotizing vasculopathiesM321, M329Systemic lupus erythematosusM330, M331, M339DermatomyositisM332PolymyositisM340, M341, M349Systemic sclerosisM340Lung involvement in systemic sclerosis*M350Sigren's diseaseM351other overlap syndromeM45Ankylosing spondylitisQ850NeurofibromatosisQ851tuberous sclerosisM261diseasenameICD-10 codedisease nameJ960acute respiratory failure	M313	Wegener's granulomatosis
M318Other specified necrotizing vasculopathiesM321, M329Systemic lupus erythematosusM330, M331, M339DermatomyositisM332PolymyositisM340, M341, M349Systemic sclerosisM340, M341, M349Systemic sclerosis*M348Lung involvement in systemic sclerosis*M350Sjogren's diseaseM351other overlap syndromeM45Ankylosing spondylitisQ850NeurofibromatosisAcute respiratory failureICD-10 codedisease nameJ960acute respiratory failure	M317	Microscopic polyangiitis
M321, M329Systemic lupus erythematosusM330, M331, M339DermatomyositisM332PolymyositisM340, M341, M349Systemic sclerosisM348Lung involvement in systemic sclerosis*M350Sjogren's diseaseM351other overlap syndromeM45Ankylosing spondylitisQ850NeurofibromatosisQ851Tuberous sclerosisAcute respiratory failureICD-10 codedisease nameJ960acute respiratory failure	M318	Other specified necrotizing vasculopathies
M330, M331, M339DermatomyositisM332PolymyositisM342PolymyositisM343Systemic sclerosisM348Lung involvement in systemic sclerosis*M350Sjogren's diseaseM351other overlap syndromeM45Ankylosing spondylitisQ850NeurofibromatosisQ851Tuberous sclerosisAcute respiratory failureICD-10 codedisease names as exclusion criteria	M321, M329	Systemic lupus erythematosus
M332PolymyositisM340, M341, M349Systemic sclerosisM348Lung involvement in systemic sclerosis*M350Sjogren's diseaseM351other overlap syndromeM45Ankylosing spondylitisQ850NeurofibromatosisQ851Tuberous sclerosisAcute respiratory failureICD-10 codedisease names as exclusion criteria	M330, M331, M339	Dermatomyositis
M340, M341, M349Systemic sclerosisM348Lung involvement in systemic sclerosis*M350Sjogren's diseaseM351other overlap syndromeM45Ankylosing spondylitisQ850NeurofibromatosisQ851Tuberous sclerosisAcute respiratory failureICD-10 codedisease names as exclusion criteria	M332	Polymyositis
M348Lung involvement in systemic sclerosis*M350Sjogren's diseaseM351other overlap syndromeM45Ankylosing spondylitisQ850NeurofibromatosisQ851Tuberous sclerosisAcute respiratory failureisease nameJ960acute respiratory failure	M340, M341, M349	Systemic sclerosis
M350Sjogren's diseaseM351other overlap syndromeM45Ankylosing spondylitisQ850NeurofibromatosisQ851Tuberous sclerosisAcute respiratory failureisease nameICD-10 codedisease names as exclusion criteria	M348	Lung involvement in systemic sclerosis*
M351other overlap syndromeM45Ankylosing spondylitisQ850NeurofibromatosisQ851Tuberous sclerosisAcute respiratory failureisiase nameICD-10 codedisease names as exclusion criteria	M350	Sjogren's disease
M45 Ankylosing spondylitis Q850 Neurofibromatosis Q851 Tuberous sclerosis Acute respiratory failure isease names as exclusion criteria J960 acute respiratory failure	M351	other overlap syndrome
Q850 Neurofibromatosis Q851 Tuberous sclerosis Acute respiratory failur ICD-10 code J960 acute respiratory failure *We already excluded these names as exclusion criteria	M45	Ankylosing spondylitis
Q851 Tuberous sclerosis Acute respiratory failure ICD-10 code disease name J960 acute respiratory failure	Q850	Neurofibromatosis
Acute respiratory failure ICD-10 code disease name J960 acute respiratory failure * We already excluded these names as exclusion criteria	Q851	Tuberous sclerosis
ICD-10 code disease name J960 acute respiratory failure * We already excluded these names as exclusion criteria	Acute respiratory failu	re
J960 acute respiratory failure * We already excluded these disease names as exclusion criteria	ICD-10 code	disease name
* We already excluded these disease names as exclusion criteria	J960	acute respiratory failure
	* We already excluded the	ese disease names as exclusion criteria

excluded disease names with pneumonia, influenza, and aspiration pneumonia and addition of that of IPF.

EXTERNAL VALIDATION OF THE CRITERIA OF A PREVIOUS STUDY

To compare the PPV with the aforementioned newly developed criteria, we externally validated the criteria of a previous study in the US [11] (pre-existing criteria) using DPC data extracted from the aforementioned eight hospitals. The inclusion criteria were as follows: 1) age ≥50 years; 2) having at least one claim to a specific diagnostic code for IPF (either ICD10 code J84.9, J84.10, J84.111, J84.112, or ICD-9 correspond); 3) having acute respiratory symptoms or ARF (J84.114, J84.9, J96.00-02, J96.20-22, J96.91-92, or ICD-9 correspond) and subsequent hospital admission; and 4) lacking secondary ILDs. [11] In accordance with the Japanese DPC data used in this study, we modified this criteria as follows: 1) age ≥ 50 years; 2) having at least one following disease name (either ICD10 code J84.9 [interstitial pneumonia (IP)] or J84.1 [IPF or idiopathic interstitial pneumonia (IIP) or pulmonary fibrosis] in three diagnosis categories (main diagnosis, diagnosis that triggered hospitalization, diagnosis using the most medical resources); 3) having at least one following disease names (ICD10 code J84.1 [acute interstitial pneumonia] or J96.0 [ARF]) in any diagnosis category, and emergency admission; and 4) lacking secondary ILDs.

STATISTICAL ANALYSIS

Interobserver agreement for the AE-IPF diagnosis between both respiratory specialists was evaluated using kappa statistics. For cases diagnosed as AE-IPF by two respiratory physicians, the interobserver agreement for AE-IPF diagnosis between both radiologists was assessed using the AC₁-index since most cases were considered to be true positive cases [19]. We calculated the PPV as true positives / (true positives + false positives) for every disease name and their combinations. Further, we calculated the 95% confidence intervals (CIs) for binomial distribution using the exact method. We could not calculate the sensitivity, specificity, and negative predictive values since we did not perform a chart review of patients without target ICD-10 codes. Validation studies for only obtaining a PPV have reported that a sample size of approximately 100 is sufficient [20], because with that number of samples, the 95% CI falls within the range of the point estimate \pm 0.1. We sought to identify patients from various disease names and search for algorithms that would improve PPV. Therefore, regarding the narrow criteria, we identified the final criteria with the largest PPV out of approximately 100 cases. Statistical analyses were performed using STATA/SE version.16.0 (Stata Corp., College Station, TX, USA).

RESULTS

This study included 822 patients; among them, 212 were diagnosed with AE-IPF by chart review. There was substantial interobserver agreement for AE-IPF diagnosis (kappa = 0.80 [0.75 to 0.85]). Among the patients who were considered to have AE-IPF by both respiratory physicians, none were considered not to have AE-IPF by both radiologists; moreover, there was excellent interobserver agreement between both radiologists (AC₁-index = 0.99 [0.98 to 1]).

Table 4 and **Table S2** show the PPV and 95% CI for each disease name. Although the disease name of AE-IPF and acute exacerbation of IIP (AE-IIP) had the highest and second-highest PPV, respectively, the number of patients was small. The PPV for all the other disease names was low.

NARROW CRITERIA

As a result of examining each of the disease names, we found that the following five disease names (AE-IIP, acute exacerbation of interstitial pneumonia, AE-IP, IPF + emergency admission, IIP + emergency admission, and IP + emergency admission) in three categories (main diagnosis, diagnosis that triggered hospitalization, or diagnosis using the most medical resources) contained many true positive patients. Therefore, we explored algorithms that would result in higher PPV for these disease names. We attempted to exclude disease names related to secondary ILDs (any of all categories) and infection (in four categories; main diagnosis, diagnosis that triggered hospitalization, diagnosis using the most medical resources, or comorbidities present at admission), and add to disease names for ARF (any of all categories) and IPF (any of all categories). Consequently, we observed an increased PPV for several combinations of disease names.

Finally, we combined the groups of disease names with a higher PPV and yielded a criteria (AE-IPF OR (AE-IIP – secondary ILDs – infection) OR (AE-IIP + IPF) OR (AE-IP – secondary ILDs – infection + ARF) with a PPV of 0.72 (95% CI 0.62 to 0.81) (**Table 4**).

BROAD CRITERIA

Using the five disease names, we searched for a criteria that would include more true-positive patients even with

Table 4 The positive predictive value (PPV) and 95% confidence intervals (CI) of patients diagnosed with acute exacerbation of idiopathic pulmonary fibrosis within each algorithm							
disease names	total (n)	True Positives	PPV	95% CI			
IPF + AE	5	4	0.8	0.28 to 0.99			
IIP + AE	32	24	0.75	0.57 to 0.89			
(IIP + AE) – secondary ILDs*	30	23	0.77	0.58 to 0.90			
(IIP + AE) – secondary ILDs + ARF*	22	17	0.77	0.55 to 0.92			
(IIP + AE) – secondary ILDs – infection	29	22	0.76	0.55 to 0.92			
(IIP + AE) – secondary ILDs – infection + ARF	21	16	0.76	0.56 to 0.90			
(IIP + AE) + IPF	6	6	1	0.54 to 1			
IP + AE	105	59	0.56	0.46 to 0.66			
(IP + AE) – secondary ILDs	95	57	0.6	0.49 to 0.70			
(IP + AE) – secondary ILDs + ARF	75	50	0.67	0.55 to 0.77			
(IP + AE) – secondary ILDs – infection	77	48	0.62	0.51 to 0.73			
(IP + AE) – secondary ILDs – infection + ARF	60	42	0.7	0.57 to 0.81			
(IP + AE) + IPF	15	9	0.6	0.32 to 0.84			
(IP + AE) + IPF – secondary ILDs – infection	12	8	0.67	0.35 to 0.90			
IPF + emergency admission	40	16	0.4	0.25 to 0.57			
IPF + emergency admission + ARF	15	10	0.67	0.38 to 0.88			
IPF + emergency admission - secondary ILDs - infection + ARF	12	8	0.67	0.35 to 0.90			
IPF + emergency admission + (IP + AE)	4	2	0.5	0.068 to 0.93			
IIP + emergency admission	152	35	0.23	0.17 to 0.31			
IIP + emergency admission + ARF	47	19	0.40	0.26 to 0.56			
IIP + emergency admission – secondary ILDs – infection + ARF	21	7	0.33	0.15 to 0.57			
IIP + emergency admission + (IP + AE)	3	2	0.67	0.094 to 0.99			
IP + emergency admission	140	38	0.27	0.20 to 0.35			
IP + emergency admission + ARF	78	27	0.35	0.24 to 0.46			
IP + emergency admission - secondary ILDs - infection + ARF	45	14	0.31	0.18 to 0.47			
final algorithm							
Narrow criteria							
(IPF + AE) OR ((IIP + AE) – secondary ILDs – infection) OR ((IIP + AE) + IPF) OR ((IP + AE) – secondary ILDs – infection + ARF)	94	68	0.72	0.62 to 0.81			
Broad criteria							
(IPF + AE) OR (IIP + AE) OR ((IP + AE) – secondary ILDs + ARF) OR (IPF + emergency admission + (ARF OR (IP + AE))) OR (IIP + emergency admission + (ARF OR (IP + AE)))	168	102	0.61	0.53 to 0.68			
Pre-existing criteria							
((IPF OR IIP OR pulmonary fibrosis OR IP) + (AIP OR ARF) + emergency admission – secondary ILDs)	126	50	0.40	0.31 to 0.49			
AE, acute exacerbation; AIP, acute interstitial pneumonia; ARF, acute respiratory failure; IIP, idiopathic interstitial pneumonia; ILDs, interstitial lung diseases; IP, intersti- tial pneumonia; IPF, idiopathic pulmonary fibrosis "+" represent AND; "-" represent NOT * disease names of secondary ILDs and ARF are described in Table 3							

a slightly inferior PPV. Finally, we created a criteria (AE-IPF OR AE-IIP OR [AE-IP – secondary ILDs + ARF] OR [IPF + emergency admission + [ARF OR AE-IP] OR [IIP + emergency admission + (ARF OR AE-IP)] with a PPV of 0.61 (95% CI 0.53 to 0.68) (**Table 4**).

PRE-EXISTING CRITERIA

The validation results for the pre-existing criteria (IPF OR IIP OR pulmonary fibrosis OR IP) + (AIP OR ARF) + emergency admissions – secondary ILDs) showed a PPV of 0.40 (95% CI 0.31 to 0.49) (**Table 4**).

DISCUSSION

Using Japanese administrative data, we created criteria for identifying patients with AE-IPF and validated the pre-existing criteria. It was difficult to accurately identify true positive AE-IPF cases only based on a single disease name. Consequently, we excluded or added various other disease names and emergency admissions, which improved the AE-IPF diagnosis accuracy. The preexisting criteria had a relatively low PPV. The PPV for the final criteria were as follows: narrow criteria, 0.72 (0.62 to 0.81); broad criteria, 0.61 (0.53 to 0.68); and pre-existing criteria, 0.40 (0.31 to 0.49).

The diagnostic accuracy of the narrow and broad criteria showed a fair PPV. Currently, the only validation study on AE-IPF derived a criteria with a PPV of 0.621 (95% CI 0.533 to 0.704) [11], which was lower and comparable to the PPV of the narrow and broad criteria, respectively. Most disease name combinations in the narrow criteria used the suffix acute exacerbation, which is unique to the DPC data and may have attributed to the higher PPV compared with that in the previous study. Meanwhile, the validation results for the pre-existing criteria revealed a relatively low PPV (0.40 [95% CI 0.31 to 0.49]). This indicates that it may be better to use the narrow or broad criteria rather than the pre-existing criteria in the Japanese DPC data.

Meanwhile, our findings are suggestive of the difficulty of AE-IPF diagnosis only based on administrative data. As shown in **Table 4**, there were only four true-positive patients with a disease name of AE-IPF. IPF is a rare disease; moreover, its diagnosis is heavily dependent on high-resolution CT (HRCT). Additionally, IPF diagnosis is sometimes difficult since it requires the exclusion of all other diseases that cause chronic fibrosis of the lungs. Furthermore, in case of acute respiratory worsening in fibrotic ILDs [21], it can be challenging for clinicians to distinguish between AE and others. Therefore, it is very difficult to accurately diagnose AE-IPF; moreover, many true positive patients could have been included among those with disease names of IIP or IP as well as IPF with or without AE. To exclude secondary ILDs, we referred to the ICD-9 and 10 codes used in previous IPF database studies [11, 17, 18]. For AE, we referred to a previous study and added a code for ARF [11]. Combining these codes with IIP and IP increased the PPV; therefore, these codes may be useful for excluding secondary ILDs and including AEs. For diseases that are rare and difficult to diagnose, a PPV of approximately \geq 70% is considered reasonable [22, 23]. Therefore, given the aforementioned difficulties in diagnosing AE-IPF, the PPVs obtained in our study could be considered reasonable.

RESEARCH IMPLICATIONS

We believe our findings regarding the criteria for identifying patients with AE-IPF can contribute to database research in Japan. Meanwhile, using the narrow criteria, only about 1/3 of the cases were true positives. To detect more patients with AE-IPF, it may be better to use the broad criteria even though it has a lower PPV. Additionally, the narrow and broad criteria are both insufficient for selecting patients with AE-IPF patients without omission. It should be recognized that some patients with disease names, including acute respiratory distress syndrome or drug-induced interstitial pneumonia, may meet the criteria for AE-IPF. Furthermore, the institutions involved in this study were tertiary hospitals that treat numerous patients with AE-IPF. Although DPC data are collected from numerous acute care hospitals, there were not all proficient in treating patients with AE-IPF; thus, our findings may not be generalizable as representative data for Japan.

We created criteria for defining AE-IPF with not very high PPV. Although the present study and a previous validation study were conducted only using disease names and hospitalization information, the DPC data have rich data on medications and procedures. Therefore, by adding these information, such as information on administration of systemic corticosteroid therapy, it may be possible to employ an algorithm with a higher PPV. Additionally, using PPV alone cannot allow for a database study that covers the entire AE-IPF population. Therefore, there is a need for studies calculating the sensitivity and specificity using methods, including random sampling or "all possible cases" sampling [24].

STRENGTH AND LIMITATIONS

Our study has several strengths. First, this is the first

validation study on AE-IPF using Japanese DPC data. Second, this was a multi-center study with a sufficient sample size. Third, AE-IPF diagnosis was more reliable because of the interpretation by two chest radiologists in addition to at least two pulmonologists.

This study had several limitations. First, since this study was conducted at tertiary emergency hospitals with respiratory specialists, it remains unclear whether it can be adapted to the entire DPC data in Japan. Therefore, our findings should be externally validated in other facilities in Japan. Second, this was a validation study of the Japanese DPC data, which is unique to Japan and does not apply to other countries. Finally, we cannot eliminate the possibility of misclassification of the IPF diagnosis (e.g., hypersensitivity pneumonitis and collagen vascular disease) or AE. However, we believe that this was reduced by the interpretation of the chest CT findings by two expert chest radiologists.

CONCLUSION

In conclusion, this study derived criteria for identifying AE-IPF from Japanese administrative data with a fair PPV. When studying AE-IPF in Japanese administrative data using the narrow or broad criteria, researchers should carefully interpret the target population.

FUNDING

The English editing fee was supported by Saiseikai Kumamoto Hospital. The funder did not play any role in the design of the study and collection, analysis and interpretation of data

CONFLICTS OF INTEREST

Keisuke Anan received a research grant from Systematic Review Workshop Peer Support Group and Fujiwara Memorial Foundation for other research purposes. Yuki Kataoka received a research grant from the Systematic Review Workshop Peer Support Group, the Japan Osteoporosis Foundation, and Yasuda Memorial Medical Foundation for other research purposes.

ACKNOWLEDGMENTS

We are grateful to Asuka Iwashita (Saiseikai Kumamoto Hospital), Hiromi Ide (Iizuka Hospital), Keiko Sakuragawa (Kobe City Medical Center General Hospital), Kyoko Wasai (Hyogo Prefectural Amagasaki General Medical Center), Hiroshi Harada (Kameda Medical Center), Megumi Kunita (Hoshigaoka Medical Center), Daiki Chinen (Okinawa Chubu Hospital), and Misao Ebihara (Japanese Red Cross Medical Center) for retrieving data. We would like to thank Editage (www.editage.com) for English language editing.

AUTHOR CONTRIBUTIONS

KA is the main author and contributed to the design of the project, data collection and analysis, and wrote the draft of the manuscript. YK contributed to the design of the project and data collection and analysis. KI, KK, TJ, KF, KT, RT, HI, TN, TK, and MI contributed data collection. YY contributed to the design of the project and supervised the study. All authors contributed to data interpretation, revised the draft, and reviewed and approved the final manuscript.

REFERENCES

1. du Bois RM. An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. *Eur Respir Rev* 2012;21:141–6.

2. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: A systematic review. *Eur Respir J* 2015;46:795–806.

3. Hutchinson JP, McKeever TM, Fogarty AW, Navaratnam V, Hubbard RB. Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. *Ann Am Thorac Soc* 2014;11:1176–85.

4. Navaratnam V, Fogarty AW, Glendening R, McKeever T, Hubbard RB. The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010. *Chest* 2013;143:1078–84.

5. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med* 2014;370:2071–82.

6. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. *Eur Respir J* 2011;37:356–63.

7. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med* 2011;183:788–824.

8. Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. *Respir Investig* 2018;56:268–91.

9. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. *J Clin Epidemiol* 2005;58:323–37.

10. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. *PLoS Med* 2015; 12:e1001885.

11. Farrand E, Vittinghoff E, Ley B, Butte AJ, Collard HR. Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF. *Respirology* 2020;25:629–35.

12. Benchimol EI, Manuel DG, To T, Griffiths AM, Rabeneck L, Guttmann A. Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data. *J Clin Epidemiol* 2011; 64:821–9.

13. Okamura S, Kobayashi R, Sakamaki T. Case-mix payment in Japanese medical care. *Health Policy* 2005;74:282–6.

14. Yasunaga H, Ide H, Imamura T, Ohe K. Impact of the Japanese Diagnosis Procedure Combination-based Payment System on cardiovascular medicine-related costs. *Int Heart J* 2005;46:855–66.

15. Raghu G, Jardin MR, Myers JL, Richeldi L, Ryerson CL, Lederer DJ, et al. Diagnosis of

idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med* 2018; 198:e44–68.

16. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. *Am J Respir Crit Care Med* 2016;194:265–75.

17. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2006;174:810–6.

18. Lai CC, Wang CY, Lu HM, Chen L, Teng NC, Yan YH, et al. Idiopathic pulmonary fibrosis in Taiwan—A population-based study.

Respir Med 2012;106:1566-74.

19. Shankar V, Bangdiwala SI. Observer agreement paradoxes in 2×2 tables: Comparison of agreement measures. *BMC Med Res Methodol* 2014;14:100.

20. Cutrona SL, Toh S, Iyer A, Foy S, Cavagnaro E, Forrow S, et al. Design for validation of acute myocardial infarction cases in Mini-Sentinel. *Pharmacoepidemiol Drug Saf* 2012;21:274–81.

21. Moua T, Westerly BD, Dulohery MM, Daniels CE, Ryu JH, Lim KG. Patients with fibrotic interstitial lung disease hospitalized for acute respiratory worsening: A large cohort analysis. *Chest* 2016;149:1205–14.

22. Segal JB, Powe NR. Accuracy of identifica-

tion of patients with immune thrombocytopenic purpura through administrative records: A data validation study. *Am J Hematol* 2004;75:12–7.

23. Wahl PM, Terrell DR, George JN, Rodgers JK, Uhl L, Cataland S, et al. Validation of claims-based diagnostic codes for idiopathic thrombotic thrombocytopenic purpura in a commercially-insured population. *Thromb Haemost* 2010;103:1203–9.

24. Widdifield J, Ivers NM, Young J, Green D, Jaakkimainen L, Butt DA, et al. Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in Ontario, Canada. *Mult Scler* 2015;21:1045–54.